GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Serum amyloid A and Interleukin-1 (IL-1) receptor antagonist (A-SAA and IL-1Ra) values;

• Comparison of pregnant women with and without GDM diagnosis
• Comparison of insulin therapy and diet-regulated GDM patients
• Comparison of pregnant women with and without LGA (large gestational age)
• Comparison of pregnant women with and without polyhydroamnios
• Investigation of its effect on pregnancy prognosis
• In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity of both parameters and cut off values.

(In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and IL-1Ra levels).

Inclusion Criteria:

• Patients with 50 gr OGTT + 100 gr OGTT + at 24-28 weeks of gestation
• Patients with 75 gr OGTT + at 24-28 weeks of gestation
• 18-42 years pregnant women

Exclusion Criteria:

• any infection
• Any known fetal chromosomal or structural anomaly
• Preterm membrane rupture
• Preterm delivery
• Preeclampsia or eclampsia
• Placenta previa